|
|
Line 534: |
Line 534: |
| "title" : "Andexanet alfa for the reversal of factor Xa inhibitor activity", | | "title" : "Andexanet alfa for the reversal of factor Xa inhibitor activity", |
| "pmid" : "26559317" | | "pmid" : "26559317" |
| },
| |
| {
| |
| "timestamp" : "2018-07-11T03:30:14Z",
| |
| "briefDesignDescription" : "Andexanet for reversing Xa inhibitors",
| |
| "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1607887",
| |
| "pageid" : 3641,
| |
| "pdfurl" : null,
| |
| "trainingLevel" : "Resident",
| |
| "citation" : "Connolly SJ, <i>et al</i>. \"Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors\". <i>The New England Journal of Medicine</i>. 2016. 375(12):1131-1141.",
| |
| "subspecialties" : "Hematology",
| |
| "expansion" : "Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors",
| |
| "statusUsableDate" : "2012-03-01",
| |
| "briefResultsDescription" : "Andexanet reverses Xa inhibitors",
| |
| "published" : "2016-09-22",
| |
| "pageName" : "ANNEXA-4",
| |
| "diseases" : "Hemorrhage",
| |
| "abbreviation" : "ANNEXA-4",
| |
| "title" : "Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors",
| |
| "pmid" : "27573206"
| |
| }, | | }, |
| { | | { |